US Pharma MarketingAbbVie makes $10.9B move for Apogee
AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug…
AbbVie is making its largest post-Allergan acquisition in a $10.9 billion move for immunology biotech Apogee Therapeutics.
Apogee's long-acting IL-13 drug, called zumilokibart, is slated to enter Phase 3 for eczema later this year. The ...
Source: Endpoints News